[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Rosenkranz, 2018 - Google Patents

Inhibition of HIV-1 Matrix Functions by Novel Inhibitor, MTI-14

Rosenkranz, 2018

View PDF
Document ID
10931304099149026471
Author
Rosenkranz A
Publication year

External Links

Snippet

Abstract Human Immunodeficiency Virus type 1 (HIV-1), the causative agent of Acquired Immunodeficiency Syndrome (AIDS), affects the lives of millions of people worldwide. Currently combination therapies represent the best treatment for patients by employing …
Continue reading at researchdiscovery.drexel.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Waheed et al. HIV type 1 Gag as a target for antiviral therapy
Tedbury et al. The role of matrix in HIV-1 envelope glycoprotein incorporation
Postler et al. The tale of the long tail: the cytoplasmic domain of HIV-1 gp41
Welch et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance
Bachand et al. Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor
von Schwedler et al. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly
Foster et al. Mechanisms of HIV-1 Nef function and intracellular signaling
Staudt et al. Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes
Zhu et al. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus
ES2462740T3 (en) Protein-protein interactions in human immunodeficiency virus
Anderson-Daniels et al. Dominant negative MA-CA fusion protein is incorporated into HIV-1 cores and inhibits nuclear entry of viral preintegration complexes
Rosenkranz Inhibition of HIV-1 Matrix Functions by Novel Inhibitor, MTI-14
Dürr et al. Targeting cellular cofactors in HIV therapy
Long et al. Identification of a potential inhibitor of the FIV p24 capsid protein and characterization of its binding site
Hübner et al. Inhibition of viral assembly in murine cells by HIV-1 matrix
Aryal Molecular Mechanism of Bruton’s Tyrosine Kinase Activation by the HIV-1 Nef Virulence Factor
Meuser Pharmacological and Biological Inhibition of HIV-1 Entry
Ciuffi et al. Interactions of processed Nef (58-206) with virion proteins of HIV type 1
Li The Discovery and Characterization of Phenylalanine-Glycine Motifs in Nucleoporin 153 that Interact with the HIV-1 Capsid
Xu Discovery and mechanism of action of a novel HIV-1 capsid inhibitor, CX06
Anderson-Daniels Molecular Mechanisms Of HIV-1 Maturation And Host Factor Utilization
Zhong Cytopmasic CPSF6 and Cyclophilin A Modulate HIV-1 Trafficking
Lusvarghi et al. Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2'site
Tien et al. Understanding regulation of HIV-1 protease precursor autoprocessing
Fischer The prevention of HIV infection and the stimulation of cells latently infected with HIV